About FibroGen, Inc.
https://www.fibrogen.comFibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs.
CEO
Thane Wettig
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-06-17 | Reverse | 1:25 |
ETFs Holding This Stock
Summary
Showing Top 3 of 17
Ratings Snapshot
Rating : D+
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
BLACKROCK FUND ADVISORS
Shares:2.44M
Value:$22.16M
BLACKROCK INC.
Shares:2.41M
Value:$21.86M
BLACKROCK INSTITUTIONAL TRUST COMPANY, N.A.
Shares:1.55M
Value:$14.04M
Summary
Showing Top 3 of 82
About FibroGen, Inc.
https://www.fibrogen.comFibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $1.08M ▼ | $6.54M ▼ | $200.64M ▲ | 18.65K% ▲ | $49.61 ▲ | $-10.87M ▲ |
| Q2-2025 | $1.35M ▼ | $13.31M ▼ | $-7.6M ▼ | -564.02% ▼ | $-1.88 ▼ | $-11.54M ▲ |
| Q1-2025 | $2.74M ▲ | $17.41M ▲ | $4.64M ▼ | 169.37% ▲ | $0.05 ▼ | $-14.18M ▲ |
| Q4-2024 | $-123.26M ▼ | $-10.93M ▼ | $17.98M ▲ | -14.59% ▲ | $4.5 ▲ | $-91.1M ▼ |
| Q3-2024 | $46.33M | $57.82M | $-17.08M | -36.87% | $-4.25 | $-12.24M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $117.97M ▲ | $137.01M ▼ | $119.53M ▼ | $-17.03M ▲ |
| Q2-2025 | $23.37M ▼ | $178.06M ▲ | $359.08M ▲ | $-223M ▼ |
| Q1-2025 | $33.61M ▼ | $165.21M ▼ | $340.14M ▼ | $-216.9M ▲ |
| Q4-2024 | $50.48M ▼ | $214.53M ▼ | $398.16M ▼ | $-225.6M ▲ |
| Q3-2024 | $131M | $264.42M | $466.12M | $-243.67M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-13.15M ▼ | $-1.85M ▼ | $87.16M ▲ | $-85.92M ▼ | $94.61M ▲ | $-1.86M ▼ |
| Q2-2025 | $-7.6M ▼ | $12.68M ▲ | $-13K ▲ | $-9K ▲ | $13.64M ▲ | $12.67M ▲ |
| Q1-2025 | $4.64M ▼ | $2.72M ▲ | $-16K ▼ | $-88K ▼ | $4.02M ▲ | $2.7M ▲ |
| Q4-2024 | $17.98M ▲ | $-30.47M ▼ | $1.72M ▲ | $5K ▲ | $-28.82M ▼ | $-30.61M ▼ |
| Q3-2024 | $-17.08M | $-8.38M | $755K | $-127K | $-9.71M | $-8.46M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Drug Product Revenue | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Thane Wettig
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-06-17 | Reverse | 1:25 |
ETFs Holding This Stock
Summary
Showing Top 3 of 17
Ratings Snapshot
Rating : D+
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
BLACKROCK FUND ADVISORS
Shares:2.44M
Value:$22.16M
BLACKROCK INC.
Shares:2.41M
Value:$21.86M
BLACKROCK INSTITUTIONAL TRUST COMPANY, N.A.
Shares:1.55M
Value:$14.04M
Summary
Showing Top 3 of 82